anmeldenNovavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024
Werte in diesem Artikel
GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows:
Conference call details: | |
Date: | May 10, 2024 |
Time: | 8:30 a.m. U.S. ET |
URL to register phone: | |
Dial-in number: | (888) 664-6383 (Domestic) or |
(+1) (416) 764-8650 (International) | |
Webcast: |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an Operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, May 10, 2024, until 11:59 p.m. U.S. ET, May 17, 2024 |
Dial-in number: | (888) 390-0541 (Domestic) or |
(+1) (416) 764-8677 (International) | |
Passcode: | 414036# |
Webcast: | ir.novavax.com/events, until June 10, 2024 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2024-financial-results-and-operational-highlights-on-may-10-2024-302138130.html
SOURCE Novavax, Inc.
Ausgewählte Hebelprodukte auf Novavax
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Novavax
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Novavax Aktie News
Novavax Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novavax nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.08.19 | Novavax Buy | H.C. Wainwright & Co. | |
| 11.12.18 | Novavax Outperform | Oppenheimer & Co. Inc. | |
| 29.03.18 | Novavax Buy | Seaport Global Securities | |
| 05.01.18 | Novavax Buy | B. Riley FBR, Inc. | |
| 20.09.16 | Novavax Neutral | Chardan Capital Markets |